Evaluating the Evidence in HR-positive/HER2-negative Metastatic Breast Cancer

CME

CDK4/6 Inhibitors in the Real World: Evaluating the Evidence in HR-positive/HER2-negative Metastatic Breast Cancer

Physicians: Maximum of 1.00 Medical Knowledge MOC point

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit™

Released: August 16, 2022

Expiration: August 16, 2023

Megan Kruse
Megan Kruse, MD
Ruth O'Regan
Ruth O'Regan, MD

Pretest

Progress
1 2
Course Completed
1.

How confident do you feel in your ability to treat patients with HR+/HER2- metastatic breast cancer?

2.

Case History: 72-year-old female presents with back pain



  • Examination reveals a left breast mass

  • Breast biopsy: invasive lobular cancer, ER-positive, PR-positive, HER2-negative

  • Systemic imaging reveals multiple lesions consistent with probable bone metastases

  • Bone biopsy consistent with breast cancer

Which of the following treatments would you consider best for this patient?

3.

Case History: 42-year-old premenopausal female presents with a breast mass



  • Imaging shows large breast mass and multiple palpable nodes

  • Biopsy reveals IDC, ER-positive, PR-negative, HER2-negative

  • Systemic staging reveals a few small liver lesions and probable bone mets

  • Liver biopsy consistent with breast primary

Based on this information, which of the following treatments would you consider for this patient?

4.

Which of the following is true regarding benefit of CDK4/6 inhibitors in patients with advanced HR+ breast cancer?

5.

Which of the following agents is associated with an intracranial clinical benefit rate of 24% in patients with HR+ breast cancer with brain metastases?